Impact of mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI) on central line-associated bloodstream infections (CLABSIs) in department of hematology at single university hospital in Japan

Journal of Infection and Chemotherapy

Volumn 24, Issue 1, 2018, Pages 31-35

  Kato, Yukiko ^a   Hagihara, Mao ^a,b   Kurumiya, Ai ^a   Takahashi, Tomoko ^a   Sakata, Miki ^a   Shibata, Yuichi ^a   Kato, Hideo ^a   Shiota, Arufumi ^a   Watanabe, Hiroki ^a   Asai, Nobuhiro ^a   Koizumi, Yusuke ^a   Yamagishi, Yuka ^a   Mikamo, Hiroshige ^a  

^a AICHI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Blood cancer; Bloodstream infections (BSIs); Central line associated bloodstream infections (CLABSIs); Department of hematology; Mucosal barrier injury laboratory confirmed bloodstream infection (MBI LCBI)

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BLOODSTREAM INFECTION; BONE TRANSPLANTATION; CATHETER INFECTION; CHILD; CLINICAL FEATURE; FEMALE; HUMAN; JAPAN; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUCOSA; MYELODYSPLASTIC SYNDROME; RETROSPECTIVE STUDY; UNIVERSITY HOSPITAL; ADVERSE DEVICE EFFECT; BACTEREMIA; BACTERIUM; CENTRAL VENOUS CATHETER; INJURIES; INTESTINE FLORA; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; BACTERIA; CATHETER-RELATED INFECTIONS; CENTRAL VENOUS CATHETERS; CHILD; FEMALE; GASTROINTESTINAL MICROBIOME; HOSPITALS, UNIVERSITY; HUMANS; JAPAN; LEUKEMIA; LYMPHOMA; MALE; MIDDLE AGED; MUCOUS MEMBRANE; RETROSPECTIVE STUDIES;

EID: 85037870544     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2017.08.013     Document Type: Article

References (23)

1. Digiovine, B., Chenoweth, C., Watts, C., Higgins, M., The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am J Respir Crit Care Med 160 (1999), 976–981.
2. Warren, D.K., Quadir, W.W., Hollenbeak, C.S., Elward, A.M., Cox, M.J., Fraser, V.J., Attributable cost of catheter-associated bloodstream infections among intensive care patients in a nonteaching hospital. Crit Care Med 34 (2006), 2084–2089.
3. Mermel, L.A., Prevention of intravascular catheter-related infections. Ann Intern Med 132 (2000), 391–402.
4. Elward, A.M., Hollenbeak, C.S., Warren, D.K., Fraser, V.J., Attributable cost of nosocomial primary bloodstream infection in pediatric intensive care unit patients. Pediatrics 115 (2005), 868–872.
5. Dudeck, M.A., Weiner, L.M., Allen-Bridson, K., Malpiedi, P.J., Peterson, K.D., Pollock, D.A., et al. National Healthcare Safety Network (NHSN) report, data summary for 2012, device-associated module. Am J Infect Control 41 (2013), 1148–1166.
6. Poutsiaka, D.D., Price, L.L., Ucuzian, A., Chan, G.W., Miller, K.B., Snydman, D.R., Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality. Bone Marrow Transpl 40 (2007), 63–70.
7. Gaur, A.H., Bundy, D.G., Gao, C., Werner, E.J., Billett, A.L., Hord, J.D., et al. Surveillance of hospital-acquired central line-associated bloodstream infections in pediatric hematology-oncology patients: lessons learned, challenges ahead. Infect Control Hosp Epidemiol 34 (2013), 316–320.
8. O'Grady, N.P., Alexander, M., Burns, L.A., Dellinger, E.P., Garland, J., Heard, S.O., et al. Guidelines for the prevention of intravascular catheter–related infections. Am J Infect Control 39 (2011), S1–S34.
9. Marschall, J., Mermel, L.A., Fakih, M., Hadaway, L., Kallen, A., O'Grady, N.P., et al. Strategies to prevent central line–associated bloodstream infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 35 (2014), 753–771.
10. Steinberg, J.P., Robichaux, C., Tejedor, S.C., Reyes, M.D., Jacob, J.T., Distribution of pathogens in central line-associated bloodstream infection among patients with and without neutropenia following chemotherapy: evidence for a proposed modification to the current surveillance definition. Infect Control Hosp Epidemiol 34 (2013), 171–175.
11. Sexton, D.J., Chen, L.F., Anderson, D.J., Current definitions of centralline associated bloodstream infections: is the emperor wearing clothes?. Infect Control Hosp Epidemiol 31 (2010), 1286–1289.
12. Fraser, T.G., Gordon, S.M., CLABSI rates in immunocompromised patients: a valuable patient centered outcome?. Clin Infect Dis 52 (2011), 1446–1450.
13. Digiorgio, M.J., Fatica, C., Oden, M., Bolwell, B., Sekeres, M., Kalaycio, M., et al. Development of a modified surveillance definition of central line-associated bloodstream infections for patients with hematologic malignancies. Infect Control Hosp Epidemiol 33 (2012), 865–868.
14. Worth, L.J., Slavin, M.A., Brown, G.V., Black, J., Catheter-related bloodstream infections in hematology: time for standardized surveillance?. Cancer 109 (2007), 1215–1226.
15. Tancrede, C.H., Andremont, A.O., Bacterial translocation and gram negative bacteremia in patients with hematological malignancies. J Infect Dis 152 (1985), 99–103.
16. Blijlevens, N.M., Donnelly, J.P., De Pauw, B.E., Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transpl 25 (2000), 1269–1278.
17. Metzger, K.E., Rucker, Y., Callaghan, M., Churchill, M., Jovanovic, B.D., Zembower, T.R., et al. The burden of mucosal barrier injury laboratory-confirmed bloodstream infection among hematology, oncology, and stem cell transplant patients. Infect Control Hosp Epidemiol 36 (2015), 119–124.
18. CDC/NHSN Surveillance Definition of Healthcare-Associated Infection and Criteria for Specific Types of Infections in the Acute Care Setting https://www.cdph.ca.gov/programs/hai/Documents/Slide-Set-20-Infection-Definitions-NHSN-2013.pdf. [Accessed 27 April 2017].
19. Steinberg, J.P., Coffin, S.E., Improving the central line-associated bloodstream infection surveillance definition: a work in progress. Infect Control Hosp Epidemiol 34 (2013), 777–779.
20. See, I., Iwamoto, M., Allen-Bridson, K., Horan, T., Magill, S.S., Thompson, N.D., et al. Mucosal barrier injury laboratory-confirmed bloodstream infection: results from a field test of a new National Healthcare Safety Network definition. Infect Control Hosp Epidemiol 34 (2013), 769–776.
21. Lalla, R.V., Bowen, J., Barasch, A., Elting, L., Epstein, J., Keefe, D.M., et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120 (2014), 1453–1461.
22. Gibson, R.J., Keefe, D.M., Lalla, R.V., Bateman, E., Blijlevens, N., Fijlstra, M., et al. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer 21 (2013), 313–326.
23. van der Velden, W.J., Herbers, A.H., Feuth, T., Schaap, N.P., Donnelly, J.P., Blijlevens, N.M., et al. Intestinal damage determines the inflammatory response and early complications in patients receiving conditioning for a stem cell transplantation. PLoS One, 5, 2010, e15156.